** Shares of drug developer Marker Therapeutics MRKR.O fall 25.5% to $3 premarket
** MRKR announces $16.1 mln private placement
** Proceeds from this financing will support the clinical development of MT-601, a next-generation T cell-based therapy for relapsed lymphoma patients - MRKR
** Investors to pay a purchase price of $3.20/shr and warrants are exercisable for $4.03/shr
** As of last close, stock has fallen 26.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。